Background and aims: It is known that the majority of critical unacknowledged hypoglycemia has an increased incidence in patients with type 1 diabetes (T1DM) with a long evolution. The aim of this research is to evaluate the variability of glucose level and hypoglycemic events in patients with type 2 diabetes (T2DM) having pharmacological interventions with hypoglycemic risk. These events are sometimes asymptomatic also in T2DM: frequently in elderly, patients with autonomic neuropathy, or having a long evolution of disease.
Material and method: This analysis includes 72 patients with T2DM, with a relative good metabolic control, and possible glucose fluctuations. Glucose variability was appreciated using continuous glucose monitoring systems (CGMS) used for more than 72 hours in hospital or ambulatory setting.
Results: The incidence, duration and severity of hypoglycemia are not correlated with HbA1c value, age, disease duration or treatment. Approximately a quarter of patients had nocturnal hypoglycemia and in 37,5% of events hypoglycemia was prolonged, more 45 minutes. Clinical manifestations in diurnal hypoglycemia were presents in only 40% of the recorded events.
Conclusions: The study suggested that CGMS is beneficial for patients with type 2 diabetes, with hypoglycemic risk and complications, to adjusted medication, education and prevention the cardiovascular events.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Seaquist ER Anderson J Childs B et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36: 1384-1395 2013.
2. Samson WK Stein LM Elrick M et al. Hypoglycemia unawareness prevention: Targeting glucagon production. Physiol Behav 162: 147-50 2016.
3. Silva TP Rolim LC Sallum Filho C Zimmermann LM Malerbi F Dib SA. Association between severity of hypoglycemia and loss of heart rate variability in patients with type 1 diabetes mellitus Diabetes Metab Res Rev 33(2) 2017
4. Jennum P Stender-Petersen K Rabøl R Jørgensen NR Chu PL Madsbad S. The impact of nocturnal hypoglycemia on sleep in subjects with type 2 diabetes. Diabetes Care 38: 2151-2157 2015.
5. Frier BM Schernthaner G HellerS. Hypogly-cemia and cardiovascular risks. Diabetes Care 34: 132-137 2011.
6. Torimoto K Okada Y Mori H Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovascular Diabetology 12:1 2013.
7. Standl E Schnell O Ceriello A. Postprandial hyperglycemia and glycemic variability- should we care? Diabetes Care 34: 120-127 2011.
8. Thompson PL Davis TME. Cardiovascular effects of glucose-lowering therapies for type 2 diabetes: new drugs in perspective. Clin Ther 39: 1012-1025 2017.
9. Mori Y Itoh Y Obata T Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 29: 143–148 2006.
10. Cui X Abduljalil D ManorB Peng K Novak V. Multi-Scale Glycemic variability: a link to gray matter atrophy and cognitive decline in type 2 diabetes. PLoS ONE 9(1): e86284 2014
11. Seaquist ER Anderson J Childs B et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36: 1384-1395 2013.
12. Samson WKStein LM Elrick M et al. Hypoglycemia unawareness prevention: Targeting glucagon production. Physiol Behav 162: 147-150. 2016
13. Jennum P Stender-Petersen K Rabøl R Jørgensen NR Chu PL Madsbad S. The impact of nocturnal hypoglycemia on sleep in subjects with type 2 diabetes. Diabetes Care 38: 2151-2158 2015.
14. Frier BM Schernthaner G Heller S. Hypogly-cemia and cardiovascular risks. Diabetes Care 34: 132-137 2011.
15. Engler B Koehler C Hoffmann C et al. Relationship between HbA1c on target risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus in Exp Clin Endocrinol Diabetes 119: 59-61 2011.
16. Fathi R Haluska B Isbel N et al. The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 43: 616–623 2004.
17. Alfadhli E Osman E Basri T. Use of a real time continuous glucose monitoring system as an educational tool for patients with gestational diabetes. Diabetol Metab Syndr 26: 48 2016.
18. Toschi E Wolpert H. Utility of continuous glucose monitoring in type 1 and type 2 diabetes in Endocrinol Metab Clin North Am 45: 895-904 2016.
19. Kilpatrick ES Rigby AS Goode K Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50: 2553-2561 2007.
20. Brod M Christensen T Thomsen TL Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 14: 665-671 2011.
21. Levy JC Davies MJ Holman RR 4-T Study- Group. Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T). Diabetes Res Clin Pract 131: 161-168 2017.
22. Green JB Bethel MA Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232–242 2015.
23. Mogensen U Andersson C Fosbøl E et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus–a retrospective nationwide study. Diabetes Obes Metab 16: 1001–1008 2014.
24. Scirica BM Bhatt DL Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317–1326 2013.